Our lab has contributed to elucidating the pro-angiogenic and pro-tumoral functions of macrophages in mouse models of cancer. We have also characterized VEGFA-independent modes of tumor angiogenesis, and illustrated the therapeutic opportunities afforded by inhibiting angiopoietin signaling in de novo models of metastatic cancer. Currently, we employ genetic cancer models and cell-engineering strategies, largely based on lentiviral gene transfer, to dissect the interactions between macrophages, blood vessels and T cells in tumors, primarily by focusing on angiogenic signaling, immune checkpoints, microRNA regulation, and secreted exosomes. By tackling these processes, we aim to reprogram the immunosuppressive tumor microenvironment to a form that enhances the efficacy of anticancer therapies and facilitates the deployment of anti-tumor immunity.

Conventional dendritic cell vaccines have delivered mixed clinical results. We have recently developed a new platform of gene-modified dendritic cells that activate the immune system against cancer. Our proprietary platform consists of a chimeric receptor, termed extracellular vesicle-internalizing receptor (EVIR), which endows dendritic cells with the ability to uptake extracellular vesicles released from the patient’s own tumor and to present EV-associated tumor antigens to the immune system, without knowledge or manipulation of tumor antigens ex vivo. EVIR-engineered dendritic cells represent a new class of tumor vaccine for personalized therapeutic applications. We are committed to clinically test our innovative vaccination strategy and deploy it to patients with cancer.